Psychedelic Clinical Trials
Find clinical trials studying psilocybin, MDMA, ketamine and other psychedelics. Many trials are actively recruiting participants who haven't found relief from conventional treatments.
Study of the Neural Circuits Underlying the Negative Emotional Bias of Depressive Disorders and Their Response to Ketamine
Centre Hospitalier St Anne
Ketamine Treatment Plans for Chronic Conditions
RIVER Foundation
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
Emory University
Comparison of Esketamine/Propofol and Methohexital Anesthesia for ECT
Medical University of Vienna
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
Massachusetts General Hospital
Glutamate Emotion Memory Study
University of Oxford
The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects
Medical University of Vienna
Long-term Observation of Participants With Mood Disorders
National Institute of Mental Health (NIMH)
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
Johns Hopkins University
University of Iowa Interventional Psychiatry Service Patient Registry
Mark Niciu
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
National Institute of Mental Health (NIMH)
ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression
University of Saskatchewan
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
National Institute of Mental Health (NIMH)
Imaging SV2A in Mood Disorders
Yale University
Neurobiology of Suicide
National Institute of Mental Health (NIMH)
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Texas A&M University
Testing the Effectiveness of Cognitive Training Among Depressed Patients Receiving Esketamine Treatment
University of Pittsburgh
Ketamine Versus Electroconvulsive Therapy in Depression
University of Ottawa
Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI Cancers
University of Utah
[11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine
National Institute of Mental Health (NIMH)
Ketamine for OUD and Comorbid Depression (OUDCD)
University of Maryland, Baltimore
KAP for Depression in Abstinent Opioid Users
Medical University of South Carolina
PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder
Usona Institute
Ketamine Interleaved With Electroconvulsive Therapy for Depression
St Patrick's Hospital, Ireland
Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy
Yale University
The Role of HNKs in the Antidepressant Effect of Ketamine
Columbia University
The UTHealth Ketamine Project
The University of Texas Health Science Center, Houston
Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects
Massachusetts General Hospital
Ketamine for Relapse Prevention in Recurrent Depressive Disorder
St Patrick's Hospital, Ireland
Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms
The University of Texas Health Science Center at San Antonio
A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder
Janssen Research & Development, LLC
The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression
Janssen Research & Development, LLC
Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer
Mayo Clinic
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression
Massachusetts General Hospital
Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression
James Murrough
Predictors of Intravenous Ketamine Response in TRD
Abraham Nunes
Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD
Apex Labs Ltd.
An EEG Study of Intravenous Ketamine for Major Depression Disorder
Ehave Inc.
Ketamine and Epigenetic Aging
TruDiagnostic
Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department
Rady Children's Hospital, San Diego
Reward Emotion Learning and Ketamine Study
University of Oxford
The Effectiveness and Safety of Esketamine in Modified Electroconvulsive Therapy
First Affiliated Hospital of Chongqing Medical University
Esketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive Disorder
Peking University
Psilocybin Versus Ketamine in Treatment-Resistant Depression
National Institute of Mental Health, Czech Republic
Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray
Lukas Pezawas
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
Sheppard Pratt Health System
The Efficacy and Safety of S-ketamine in Elective Cesarean Section
Beijing Obstetrics and Gynecology Hospital
Imaging Neural Correlates of Ketamine Using PET/MR
Medical University of Vienna
Browse by Condition
View all conditions →How to Join a Clinical Trial
Clinical trials are research studies that test new treatments. Participating can give you access to cutting-edge therapies while contributing to medical science. Each trial has specific eligibility criteria based on the research goals.
1. Review
Read the trial details, eligibility criteria, and what participation involves.
2. Contact
Reach out to the study team using the contact information provided.
3. Screen
Complete the screening process to determine if you're eligible.